Matthew Gall
About Matthew Gall
Matthew Gall, age 49, is Chief Financial Officer and Treasurer of Kalaris Therapeutics, Inc. (KLRS) effective November 3, 2025, and serves as the Company’s principal financial officer . He previously served as CFO of iTeos Therapeutics (June 2020–August 2025) and held senior corporate development and treasury roles at Sarepta Therapeutics (2013–2020); he holds a B.S. from Bowling Green State University and an MBA from The University of Chicago Booth School of Business . The filings reviewed do not disclose executive-specific TSR, revenue growth, or EBITDA growth metrics for his tenure; his annual bonus is tied to Board-defined corporate and individual objectives without published metric weightings .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Kalaris Therapeutics, Inc. | Chief Financial Officer & Treasurer; Principal Financial Officer | Nov 2025–present | Appointed CFO and principal financial officer; responsible for finance leadership and reporting |
| iTeos Therapeutics, Inc. | Chief Financial Officer | Jun 2020–Aug 2025 | Served as CFO of a clinical-stage biopharmaceutical company |
| Sarepta Therapeutics, Inc. | SVP Corporate Development | Nov 2019–Jun 2020 | Led corporate development; senior role at commercial-stage biotech |
| Sarepta Therapeutics, Inc. | VP Business Development & Corporate Treasurer | Mar 2018–Nov 2019 | Combined BD and treasury leadership |
| Sarepta Therapeutics, Inc. | Senior Director, Head of Business Development & Treasurer | Sep 2015–Mar 2018 | Headed BD; treasury responsibilities |
| Sarepta Therapeutics, Inc. | Director of Corporate Development | Jan 2014–Aug 2015 | Corporate development execution |
| Sarepta Therapeutics, Inc. | Various roles | Jan 2013–Jun 2020 | Progressive finance and BD roles over ~7 years |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Not disclosed | — | — | Employment agreement permits one outside board seat during tenure; no current external boards disclosed in filings |
Fixed Compensation
| Component | Value/Terms | Notes |
|---|---|---|
| Base Salary | $485,000 per year | Set in Employment Agreement; subject to annual review |
| Target Bonus | 40% of base salary | Discretionary; based on corporate and individual objectives; 2025 bonus pro-rated from start date; paid by Mar 15 following year if earned |
| Benefits | Standard executive benefits | Health/disability/retirement plans per Company policy |
| Expense Reimbursement | Business expenses reimbursed | Per Company policy and Section 409A rules |
Performance Compensation
Annual Cash Incentive Structure
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Board-defined corporate and individual objectives | Not disclosed | 40% of base salary (pro-rated for 2025) | Not disclosed | Not yet determined for 2025 | Cash when approved; paid by Mar 15 following year |
Equity Awards (Time-Based)
| Security | Grant Date | Shares | Exercise Price | Vesting Schedule | Plan |
|---|---|---|---|---|---|
| Incentive Stock Option | Nov 3, 2025 (Effective Date) | 235,000 | Closing price on Nasdaq on grant date (exact $ not disclosed) | 25% on first anniversary; remaining 75% in 36 equal monthly installments (4-year total), subject to continued service | 2020 Stock Option and Grant Plan (as amended) |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial Ownership (Initial) | Form 3 filed Nov 3, 2025 reports “No securities are beneficially owned” |
| Options Outstanding | 235,000 shares granted at hire; initially unexercisable; time-based vesting over 4 years |
| Pledging/Hedging Policy | Company policy prohibits derivative transactions, short sales, and pledging of company stock by executives and directors |
| Clawback Policy | SEC/Nasdaq-compliant clawback adopted Oct 26, 2023; recovery of incentive comp tied to financial reporting measures upon required restatement (3-year lookback) |
Employment Terms
| Provision | Terms |
|---|---|
| At-will Employment; Role | CFO reporting to CEO; primarily based in Berkeley Heights, NJ; expected travel; full-time devotion to Company |
| Non-Compete/Non-Solicit; IP/Confidentiality | Executed as condition of employment; included in Restrictive Covenant Agreements |
| Severance (non-CoC) | If terminated without cause or resigns for good reason more than 3 months before or more than 12 months after a CoC: 9 months base salary continuation; Company-paid share of health premiums under COBRA up to 9 months (subject to release and compliance) |
| Change-in-Control (double-trigger) | If terminated without cause or resigns for good reason within 3 months before or 12 months after a CoC: 12 months base salary; lump-sum equal to 100% of Target Bonus; Company-paid share of health premiums under COBRA up to 12 months; full acceleration of time-based unvested equity (subject to release and compliance) |
| Section 409A | Severance payments structured to comply with IRC §409A; specified employee delay rules apply |
| Indemnification | Standard officer indemnification agreement executed |
Investment Implications
- Pay-for-performance alignment: Fixed pay is modest relative to peer CFOs; variable cash comp is at 40% target and tied to Board-set objectives, while equity is time-based rather than performance-based—expect limited near-term PSU-driven alignment and more retention-oriented RSUs/options .
- Vesting and insider supply: Initial Form 3 shows zero beneficial ownership; the 4-year option vest schedule reduces near-term selling pressure; monitor for Form 4 filings as tranches vest and for any additional grants at year-end .
- Retention and CoC economics: Double-trigger CoC protection (12 months base + 100% target bonus + time-based equity acceleration) reduces exit friction in a sale, while non-CoC severance (9 months base) provides moderate protection—overall suggests balanced retention incentives without excessive golden parachute risk .
- Governance context: KLRS is a Nasdaq “controlled company,” and its compensation committee is not entirely independent; however, prohibitions on hedging/pledging and a compliant clawback policy mitigate alignment risks; note EGC status reduces say-on-pay disclosures/votes .
- Execution risk: As new CFO and principal financial officer, Gall has attested to internal controls and fair presentation in Q3’25 10-Q certifications; his deep BD/treasury background at Sarepta may benefit capital strategy for ophthalmology pipeline execution .